Lawmakers Urge FDA to Restrict Chinese Clinical Data After Trial Deaths
Two Republican legislators have called on the FDA to reject clinical trial data from Chinese sites unless those sites have been audited by the agency recently. They also want a comprehensive review of existing products that rely on Chinese-generated data. The request follows reported deaths in investigator-initiated trials in China.
The lawmakers’ request targets a specific regulatory gap: FDA acceptance of clinical trial data from Chinese sites without recent on-site verification. Their proposal would require audits before such data can support drug approvals, and would also trigger a retrospective review of already-approved products built on Chinese-generated evidence. The trigger for this action is a series of reported deaths in investigator-initiated trials conducted in China, which raised concerns about oversight and data reliability.
This move reflects broader tensions in global drug development, where lower-cost trial sites in China have become common. The FDA has historically relied on foreign data when it meets certain standards, but the lawmakers argue that recent incidents undermine confidence. The review would likely affect pharmaceutical companies with ongoing or completed trials in China, potentially delaying approvals or requiring supplemental data.
This could reshape how drugmakers plan global trials, potentially increasing costs and timelines if Chinese sites face stricter scrutiny. Patients may see delayed access to new therapies, but also gain reassurance about safety if audits catch problems. The review of existing products could lead to label changes or withdrawals, affecting physicians and patients who rely on those drugs. The impact would ripple through research partnerships and international regulatory norms, though the final outcome depends on FDA action and industry responses.